efpia.eu

Investing in well-designed cardiometabolic health checks linked to care pathways would significantly reduce burden of cardiovascular disease in Europe Cardiovascular disease (CVD) is often discussed through statistics, targets, and system costs. Those figures are important, but they can sometimes obscure a simple reality: across Europe, almost everyone will know someone affected by heart disease, stroke, diabetes, obesity, or high blood pressure.

EFPIA submission to the EU Biotech Act consultation

Join us on 7 September for the annual EFPIA Rentrée, marking the start of the new policy season. Bringing together EFPIA members, colleagues and partners, the reception provides an opportunity to reconnect after the summer break, exchange perspectives on the months ahead, and continue the conversations that will shape our work throughout the rest of the year. Event details: ​Monday, 7 September 2026 18:30–20:30 CEST Residence Palace, Rue de la Loi 155, Brussels Register here by 21 August.

Join us on 7 September for the annual EFPIA Rentrée, marking the start of the new policy season. ​Bringing together EFPIA members, colleagues and partners, the reception provides an opportunity to reconnect after the summer break, exchange perspectives on the months ahead, and continue the conversations that will shape our work throughout the rest of the year. Event details: ​📅 Monday, 7 September 2026 🕡 18:30–20:30 CEST 📍 Residence Palace, Rue de la Loi 155, Brussels Register here by 21 August.

EFPIA response to UK Switzerland Free Trade Agreement This announcement signals clear leadership from the UK and Switzerland on the importance of a strong intellectual property (IP) framework to support life sciences innovation and contains truly world-leading IP provisions. The agreement sends a clear signal to global companies that both regions are committed to supporting and attracting pharmaceutical investment.

German Parliament passes Statutory Health Insurance Contribution Stabilization Act: EFPIA response "The health reforms passed by the German Parliament send a concerning signal about how Germany values its role as a leader in pharmaceutical innovation and the significant benefits it enjoys from a thriving Industry. Deprioritising investment in innovative medicines risks undermining Germany's long-term competitiveness, economic resilience and health security.

Europe produces world-class cancer research, yet too often patients wait too long to benefit from scientific progress. Momentum 2026 is a new European high-level conference designed to help close that gap. Convened by the Swedish Cancer Society together with partners including UICC, IARC, Cancer Patients Europe and EACS, Momentum will bring together leaders from research, healthcare, policy, industry and patient advocacy in Stockholm on 14–16 October 2026.

With over 300 authorities and experts sharing their perspectives, the PRIVACY SYMPOSIUM provides a venue for data governance professionals, experts, authorities and researchers to meet and discuss: Latest and upcoming changes in data processing regulations International cooperation and convergence in data governance Emerging technologies and regulatory compliance Future demands and needs for data compliance Research and innovation in data governance and compliance Enhance your skills through...

EFPIA Newsletter 02 July 2026 Turning EU excellence in science into commercial success could add more than €120billion to EU economy in 10 years EFPIA's latest competitiveness analysis, now expanded to include Japan, shows that the EU and Japan are at a similar crossroads. Both have strong scientific foundations and globally recognised pharmaceutical industries, yet face increasing competition from countries that are making life sciences innovation a strategic economic and industrial priority.

EFPIA welcomes the publication of the very first Joint Clinical Assessment (JCA) report developed under the frame of the EU HTA Regulation EFPIA welcomes the publication of the very first Joint Clinical Assessment (JCA) report developed under the frame of the EU HTA Regulation. This is the culmination of 14 months of joint work and marks a significant step in operationalising EU-level cooperation on health technology assessment.